Site	Modifying Enzyme	Cellular Function	Disease or Knockout Phenotype
Phosphorylation	N-Terminal: S6, S9, S15, T18, S20	ATM, DNAPK, CK1 ERKs, ATR, p38 kinase, mTOR, Chk1/Chk2, JNK, MAPKAP2, Hipk4	Activated by DNA damage, UV light, ionizing radiation, replicative senescence, or phosphatidylcholines. N-terminal phosphorylation causes p53 stabilization by inhibiting the p53-MDM2 interaction.	Knockin mice carrying separate analogs to human Ser18/ Ser23 mutation are phenotypically normal. Thymocytes from Ser18 mutant mice are susceptible to ionizing radiation-induced apoptosis, whereas S23 mutation in ES cells and MEFs is dispensable for p53 stabilization and activation. Ser18/Ser23 double mutant knockin mice display reduced apoptosis in thymocytes and develop some malignancies. Very rare mutations reported in human tumors.
	S33, S37, S36, S46, T55, T81	GSK3β, p38 kinase, ATR, DNAPK, JNK, AMPKalpha HIPK2, DYKR2, ERK2, TAF1	Activation by UV light (S33, S37, S46, Thr81), H2O2 treatment (S33), γ-radiation, DNA damage (S37), and glucose deprivation (Ser46). Phosphorylation leads to stabilization and promotes p53 transcriptional activity to regulate p53-mediated cell-cycle arrest and apoptosis.	Very rare mutations reported in human tumors.
	S149, T150, T155	CSN-associated kinase complex	Activated in unstressed cells. Promotes p53 degradation.	Very rare mutations reported in human tumors.
	S315, S376, S378, S392	PKC, PKR, GSK3β FACT-CK2, p38 kinase CDK (cdc2/ck2), AURKA	Activated by UV light (CDK/GSK3β, FACT-CK2, p38 kinase), AURKA over-expression, and interferon signaling (PKR) S351 phosphorylation activates p53-mediated transcription to regulate apoptosis and cell cycle. PKC constitutively phosphorylates p53 at S376 and S378 in unstressed cells, IR stress leads to dephosphorylation. S392 phosphorylation promotes sequence-specific p53 DNA binding.	Knockin of S392 mouse analog (S389) is phenotypically normal. p53 transcriptional activation is partially compromised in cells isolated from knockin mice. Very rare mutations have been reported for individual sites in human tumors.
Acetylation	K120	hMOF, Tip60	K120 acetylation is promoted upon DNA damage. Acetylation at K120 is crucial for p53-mediated apoptosis via BAX and PUMA. K120 acetylation is dispensable for cell-cycle regulation and growth arrest. p53 acetylated at K120 accumulates at proapoptotic target genes.	K120 mutations to Arg, Glu, or Met have been reported in human tumors. Effect of K120 point mutations in animal models will need to be determined.
	K164	p300 / CBP	Acetylation is induced by DNA damage and HDAC inhibitor treatment. K164 mutation does not affect DNA binding. Acetylation is required for growth arrest and apoptosis.	Mutations of K164 are reported in human tumors.
	K320	PCAF	Acetylation of K320 by PCAF is induced by DNA damage. K320 acetylation increases p53 DNA-binding capability. p53 K320 acetylation state effects transcriptional activity.	Knockin experiments of the mouse homolog K317R, mimicking p53 unacetylated at K320, enhance p53-mediated apoptosis after DNA damage in all cell types analyzed. Very rare mutations reported in human tumors.
	K370, K372, K373, K381, K382, K386	p300/CBP	C-terminal acetylation levels are enhanced upon stress. Acetylation levels increase upon HDAC inhibitor (TSA, nicotinamide) treatment. C-terminal acetylation enhances p53 sequence-specific DNA-binding activity. Acetylation promotes CBP/p300 recruitment and target gene activation. p53 stability is affected by C-terminal acetylation due to inhibition of ubiquitination at acetylated lysines. p53 is deacetylated by HDACs and Sirt1. Deacetylation by Sirt represses p53-dependent apoptosis in response to DNA damage and oxidative stress.	Knockin experiments in mice introducing p53 with the C-terminal lysines mutated (6KR/7KR) produced viable and phenotypically normal animals. C-terminal KR stem cells, MEFs, and thymocytes show normal p53 stabilization after DNA damage, yet p53 target gene expression is impaired in promoter-specific fashion. Very rare mutations reported in human tumors.
Ubiquitination and UB-like Modification	UB: K370, K372, K373, K381, K382, K386	MDM2 Arf-BP1, COP1, and Pirh2	MDM2-mediated polyubiquitination leads to p53 degradation. monoubiquitination of p53 results in nuclear export. Arf-BP1, COP1, and Pirh2 all ubiquitinate p53 and target it for proteasomal degradation. HAUSP deubiquitinates p53 as well as regulates p53 via deubiquitination of MDM2 and MDMX.	Knockin experiments in mice introducing p53 with the C-terminal lysines mutated (6KR/7KR) produced viable and phenotypically normal animals. C-terminal KR stem cells, MEFs, and thymocytes display normal p53 stabilization after DNA damage, yet p53 target gene expression is impaired in a promoter-specific fashion. Knockin experiments of the mouse homolog K317R, mimicking p53 unacetylated at K320, enhance p53-mediated apoptosis after DNA damage in all cell types analyzed. Very rare mutations reported in human tumors.
	SUMO: K386	PIAS, PIASxβ	Functional consequences are unclear. Both activation and suppression of transcriptional regulation have been reported.
	NEDD8: K320 K321, K370, K372, K373	FBXO11, MDM2	Neddylation of p53 inhibits transcriptional activity.
Methylation	K370	Smyd2	Inhibition of p53-promoter association resulting in p53 target gene repression.	Knockin experiments in mice introducing p53 with mutated C-terminal lysines (6KR/7KR) produced viable and phenotypically normal animals. C-terminal KR stem cells, MEFs, and thymocytes show normal p53 stabilization after DNA damage, yet p53 target gene expression is impaired in promoter-specific fashion. Modest effect of C-terminal lysine mutant knockins implies limited effect of p53 regulation via single site metylation. Very rare mutations reported in human tumors.
	K372	Set7/9	Methylation stabilizes p53 and promotes nuclear localization to upregulate p53 target gene expression. Blocks Smyd-mediated K370 methylation.
	K382	Set8/PR-Set7	Suppresses p53 mediated transcription. Augments proapoptotic and checkpoint activation.
Others	O-GlcNAc: Ser149	O-GlcNAc transferase, O-GLcNAcase	Stabilization of p53 by blocking ubiquitination-mediated proteolysis. Modification prevents T155 phosphorylation.	In vivo role of these modifications is not yet determined. Very rare mutations reported in human tumors.
	ADP-ribosylation: E258, D259, E271	PARP-1	ADP-ribosylation prevents p53-Crm1 interaction, resulting in nuclear accumulation of p53 due to inhibition of nuclear export of p53.